S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
OTCBB:AMBS

Amarantus BioScience Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

Headlines

Todos Medical CEO Releases Letter to Shareholders
September 18, 2020 |  finance.yahoo.com
Nationwide On-Site Coronavirus Testing Program
July 6, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCBB:AMBS
CUSIPN/A
CIKN/A
Phone650-862-5391
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.48 out of 5 stars

Medical Sector

1556th out of 1,960 stocks

Biotechnology Industry

72nd out of 119 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
30 days | 90 days | 365 days | Advanced Chart

Receive AMBS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMBS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amarantus BioScience (OTCBB:AMBS) Frequently Asked Questions

What stocks does MarketBeat like better than Amarantus BioScience?

Wall Street analysts have given Amarantus BioScience a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amarantus BioScience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Amarantus BioScience's earnings last quarter?

Amarantus BioScience Holdings, Inc. (OTCBB:AMBS) released its quarterly earnings data on Monday, November, 23rd. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.77) by $0.21.
View Amarantus BioScience's earnings history
.

Who are Amarantus BioScience's key executives?

Amarantus BioScience's management team includes the following people:
  • Mr. Gerald E. Commissiong, CEO, Pres & Director (Age 38)
  • Dr. John Wesley Commissiong, Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 76)
  • Mr. Robert Lewis Harris, Compliance Officer & Director (Age 77)
  • Dr. Elise Brownell, Sr. VP of Operations & Project Management
  • Aimee Boutcher, Director of Investor Relations
  • Dr. Ravi Kiron, Sr. VP of Bus. Devel. (Age 61)
  • Dr. Paula T. Trzepacz, Chief Medical Advisor to Elto Pharma and Breakthrough Diagnostics
  • Dr. Brian E. Harvey, Chief Regulatory Advisor & Member of Board of Advisors
  • Dr. Richard Kagan M.D., Chief Medical Advisor to Cutanogen Corp.
  • Dr. Owen Garrick, Corp. Advisor

Who are some of Amarantus BioScience's key competitors?

What other stocks do shareholders of Amarantus BioScience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarantus BioScience investors own include Energous (WATT), (SNY), Novavax (NVAX), Amgen (AMGN), Co-Diagnostics (CODX), Quest Diagnostics (DGX), The Walt Disney (DIS), Dynavax Technologies (DVAX), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

What is Amarantus BioScience's stock symbol?

Amarantus BioScience trades on the OTCBB under the ticker symbol "AMBS."

How do I buy shares of Amarantus BioScience?

Shares of AMBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarantus BioScience's official website?

The official website for Amarantus BioScience is www.amarantus.com.

How can I contact Amarantus BioScience?

The company can be reached via phone at 650-862-5391.


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.